MangoRx Shakes Up TRT Market With $99 All-Inclusive Telehealth Plan

DALLAS, TX – February 19, 2026 – Telehealth company Mangoceuticals, Inc. (NASDAQ: MGRX) has announced staggering initial results for a new, aggressively priced Testosterone Replacement Therapy (TRT) program, sending ripples through the competitive men's health market. The company, operating under the brand MangoRx, reported a 336% month-over-month sales increase for its injectable TRT program since its launch in mid-December, coupled with a 54% reduction in the cost to acquire each new customer.

The program's disruptive hook is its all-inclusive $99 per month price tag, which covers doctor consultations, lab work, and the prescribed medication. This model aims to simplify and democratize access to TRT, a treatment for hypogonadism (low testosterone) that is gaining awareness among an aging population. The company's announcement positions TRT as its primary growth engine, signaling a strategic pivot to capture a larger share of the burgeoning men's hormone health sector, which is estimated to be a $2.2 billion global market in 2025.

“We are encouraged by this initial customer demand and sales acceleration in our injectable TRT product, which we believe demonstrates the value of our innovative approach to men’s hormone health and underscores TRT as our key strategic focus,” stated Jacob Cohen, Founder and CEO of Mangoceuticals Inc., in a press release. He emphasized that the combination of effective solutions and streamlined telehealth delivery aims to support more men seeking reliable and discreet care.

The $99 Disruption in a Crowded Field

MangoRx’s pricing strategy places it in direct and aggressive competition with a host of other digital health platforms. The online TRT space is a crowded battleground where convenience and cost are key differentiators. An analysis of the market reveals a wide spectrum of pricing models, making MangoRx's straightforward, all-inclusive offer particularly noteworthy.

Competitors like TRT Nation and Hims offer similar plans around the $99 monthly mark, establishing a clear value tier in the market. However, other providers feature more complex pricing. For instance, some advertise a low monthly rate but require a significant upfront annual payment, while others, like Hone Health, separate their membership fee (around $129-$149/month) from the medication cost. More premium or specialized clinics can easily run from $150 to over $250 per month, often with additional fees for initial lab work or consultations. By bundling all necessary components—consultations, labs, and medication—into a single, transparent monthly fee, MangoRx is applying significant pressure on competitors and challenging the industry's pricing norms.

The sustainability of such a low price point is a critical question. The primary costs in a TRT program include the medication itself (injectable testosterone is relatively inexpensive), physician consultations, and, most significantly, the lab work required for diagnosis and ongoing monitoring. Initial comprehensive blood panels can cost hundreds of dollars, with follow-up tests adding to the expense. For the $99 model to be viable long-term, MangoRx must be leveraging significant economies of scale, securing highly favorable rates with partner labs and pharmacies, and operating with extreme efficiency. The reported 54% drop in customer acquisition cost is a crucial piece of this puzzle, as high marketing spend can quickly erode the thin margins of a low-cost subscription service.

Navigating the Telehealth and Regulatory Frontier

The rapid growth of telehealth TRT services like MangoRx’s operates within a complex and evolving regulatory landscape. Testosterone is classified as a Schedule III controlled substance by the Drug Enforcement Administration (DEA), which traditionally required an in-person medical evaluation before a prescription could be issued.

During the COVID-19 Public Health Emergency, the DEA enacted temporary flexibilities, waiving the in-person requirement and allowing providers to prescribe controlled substances based solely on a telehealth consultation. This change was the catalyst for the boom in online TRT clinics. However, these flexibilities, while extended multiple times, are not permanent. The DEA has proposed new rules that would largely restore the in-person visit requirement for the initial prescription of controlled substances. This presents a significant potential hurdle for the purely virtual model that MangoRx and its competitors rely on. The outcome of this regulatory debate will be a defining factor in the future of the entire industry.

Beyond regulatory challenges, the rise of low-cost, high-volume TRT services raises important questions about the quality and safety of patient care. Medical organizations like the Endocrine Society have established clear clinical guidelines for diagnosing and treating hypogonadism, emphasizing the need for thorough evaluation to rule out other causes of symptoms and careful monitoring to manage potential side effects. The promise of telehealth is increased access, but the potential pitfall is the risk of a “one-size-fits-all” approach that may not provide the individualized care required for hormone therapy. Ensuring that rapid growth does not come at the expense of rigorous medical oversight is the central challenge for all providers in this space.

The Future of Specialized Virtual Care

MangoRx’s success with TRT is emblematic of a broader trend in healthcare: the evolution of telemedicine from a platform for general urgent care to a provider of specialized, ongoing treatment for chronic and lifestyle-related conditions. Companies are increasingly building brands around specific health niches, such as erectile dysfunction, hair loss, weight management, and hormone optimization, offering a direct-to-consumer experience that bypasses many of the hurdles of traditional healthcare.

As stated in its announcement, MangoRx plans to continue this evolution, expanding its platform to become a more well-rounded provider of men’s health solutions. This strategy aims to build a comprehensive ecosystem of services, increasing the lifetime value of each customer and solidifying the company's market position. The initial success of its $99 TRT program serves as a powerful proof of concept, demonstrating a clear and potent demand for accessible, affordable, and discreet medical treatments. How the company balances explosive growth with the imperatives of quality care and a shifting regulatory environment will ultimately determine its long-term impact on the future of men's health.